Brokerages Set Catalent Inc (CTLT) Price Target at $29.17
Shares of Catalent Inc (NASDAQ:CTLT) have earned an average rating of “Buy” from the ten brokerages that are currently covering the firm. Four equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $29.17.
A number of research analysts recently weighed in on the stock. Jefferies Group LLC increased their price objective on shares of Catalent from $29.00 to $32.00 and gave the company a “hold” rating in a research report on Monday, February 27th. TheStreet upgraded shares of Catalent from a “d+” rating to a “c” rating in a research report on Monday, February 6th. Finally, Goldman Sachs Group Inc assumed coverage on shares of Catalent in a research report on Thursday, December 1st. They set a “neutral” rating and a $25.00 price objective on the stock.
Your IP Address:
Shares of Catalent (NASDAQ:CTLT) opened at 28.45 on Thursday. The stock has a market cap of $3.55 billion and a price-to-earnings ratio of 39.57. The stock’s 50 day moving average is $28.51 and its 200 day moving average is $26.06. Catalent has a 52 week low of $20.94 and a 52 week high of $32.24.
Catalent (NASDAQ:CTLT) last issued its earnings results on Monday, February 6th. The company reported $0.27 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.27. The firm earned $483.70 million during the quarter, compared to the consensus estimate of $474.07 million. The company’s quarterly revenue was up 6.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.36 EPS. On average, equities analysts forecast that Catalent will post $1.38 EPS for the current year.
In related news, insider John R. Chiminski sold 73,819 shares of the stock in a transaction that occurred on Monday, March 20th. The shares were sold at an average price of $28.62, for a total transaction of $2,112,699.78. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Donald E. Morel, Jr. acquired 10,000 shares of the stock in a transaction that occurred on Wednesday, February 15th. The shares were bought at an average price of $29.27 per share, for a total transaction of $292,700.00. The disclosure for this purchase can be found here.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Forward Management LLC increased its position in shares of Catalent by 1.5% in the third quarter. Forward Management LLC now owns 14,831 shares of the company’s stock worth $383,000 after buying an additional 225 shares during the period. Profund Advisors LLC increased its position in shares of Catalent by 1.2% in the third quarter. Profund Advisors LLC now owns 22,994 shares of the company’s stock worth $594,000 after buying an additional 275 shares during the period. LS Investment Advisors LLC increased its position in shares of Catalent by 5.2% in the third quarter. LS Investment Advisors LLC now owns 7,499 shares of the company’s stock worth $194,000 after buying an additional 368 shares during the period. Bronfman E.L. Rothschild L.P. increased its position in shares of Catalent by 7.6% in the third quarter. Bronfman E.L. Rothschild L.P. now owns 5,673 shares of the company’s stock worth $147,000 after buying an additional 400 shares during the period. Finally, Municipal Employees Retirement System of Michigan increased its position in shares of Catalent by 1.4% in the third quarter. Municipal Employees Retirement System of Michigan now owns 48,140 shares of the company’s stock worth $1,244,000 after buying an additional 680 shares during the period.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Stock Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related stocks with our FREE daily email newsletter.